Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Nitrates or nitrites or nitric acid or nitrogen oxides
Patent
1997-01-17
1999-05-18
Harrison, Robert H.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Nitrates or nitrites or nitric acid or nitrogen oxides
514822, A61K33/00
Patent
active
059049383
ABSTRACT:
Disclosed are methods of treating, inhibiting or preventing vascular thrombosis or arterial restenosis in a mammal. The disclosed methods include causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (NO). Also disclosed are methods that include the administration of the following types of agents in conjunction with inhaled nitric oxide: compounds that potentiate the beneficial effects of inhaled nitric oxide, and antithrombotic agents that complement or supplement the beneficial effects of inhaled nitric oxide.
REFERENCES:
patent: 3785377 (1974-01-01), Jorgensen
patent: 4010897 (1977-03-01), Treharne et al.
patent: 4287040 (1981-09-01), Alamaro
patent: 4297123 (1981-10-01), Wyse et al.
patent: 4336798 (1982-06-01), Beran
patent: 4534343 (1985-08-01), Nowacki et al.
patent: 4592348 (1986-06-01), Waters et al.
patent: 4667668 (1987-05-01), Wetterlin
patent: 4852561 (1989-08-01), Sperry
patent: 4877589 (1989-10-01), O'Hare
patent: 4915915 (1990-04-01), Treharne et al.
patent: 4954526 (1990-09-01), Keefer et al.
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5185376 (1993-02-01), Diodati et al.
patent: 5208233 (1993-05-01), Keefer et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5396882 (1995-03-01), Zapol
patent: 5427797 (1995-06-01), Frostell et al.
patent: 5570683 (1996-11-01), Zapol
patent: 5681278 (1997-10-01), Igo et al.
Allen and Hanbury, Product Information Bulletin on Ventolin, (1990).
Zapol, U.S. Ser. No. 07/622,865, Dec. 5, 1990.
Zapol, U.S. Ser. No. 07/767,234, Sep. 27, 1991.
Zapol, U.S. Ser. No. 07/904,117, Jun. 25, 1992.
Zapol, U.S. Ser. No. 08/036,522, Mar. 24, 1993.
Zapol, et al., U.S. Ser. No. 08/353,508, Dec. 9, 1994.
Zapol, U.S. Ser. No. 07/850,383, Mar. 11, 1992.
Zapol, U.S. Ser. No. 08/222,256, Apr. 1, 1994.
Altabef et al., Intravenous Nitroglycerin for Uterine Relaxation of an Inverted Uterus, Am. J. Obstet. Gynecol. 166:1237-1238, (1992).
Anngard, "Nitric Oxide: Mediator, Murderer, and Medicine," Lancet, 343:1199-1205 (1994).
Archer, et al., "Hypoxic Pulmonary Vasoconstriction is Enhanced by Inhibition of the Synthesis of an Endothelium Relaxing Derived Factor," Biochem. Biophys. Res. Commun. 164:1198-1205 (1989).
Archer, et al., "Comparison of the Hemodynamic Effects of Nitric Oxide and Endothelium-Dependent Vasodilators in Intact Lungs," J. App. Physiol. 68:735-747 (1990).
Arnold, et al., "Cigarette-Smoke Activates Guanylate Cyclase and Increase Guanosine 3', 5' -Monophosphate in Tissues", Science, 198:934-936 (1977).
"Asthma", Ch. 14-II, Scientific American Medicine, vol. 2, Scientific American, Inc., pp. 1-18 (1988).
Benzing et al., "Nitric Oxide Inhalation. Application and Continuous Measurment of Inhaled Concentration," Anaesthesist (1993) 42:175-178 (Abstract in English).
Blomqvist, et al., "Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator Reversing Human Hypoxic Pulmonary Vasoconstriction (HPV)," Circulation 84:361 (1991).
Boje, et al., "Endothelial Nitric Oxide Generating Enzyme(s) in the Bovine Aorta: Subcellular Location and Metabolic Characterization," Am. Soc. Pharmacol. Exp. Ther. 253:20-26 (1990).
Borland, et al., "A Simultaneous Single Breath Measurement of Pulmonary Diffusing Capacity with Nitric Oxide and Carbon Monoxide," Eur. Respir. J. 2:56-63 (1989).
Brashers, et al., "Augmentation of Hypoxic Pulmonary Vasoconstriction in the Isolated Perfused Rat Lung by in Vitro Antagonists of Endothelium-Dependent Relaxation," J. Clin. Invest. 82:1495-1502 (1988).
Brune, et al., "Activation of a Cystolic ADP-Ribosyltransferase by Nitric Oxide-Generating Agents," J. Biol. Chem. 264:8455-8458 (1989).
Buga, et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," Eur. J. Pharmacol. 161:61-72 (1989).
Contractor, et al., "Development and Evaluation of an Inhalation Aerosol of Nitroglycerin," J. Pharm. Sci. 63:907-911 (1974).
Cremona, et al., "Endothelium-Derived Relaxing Factor and the Pulmonary Circulation," Lung 169:185-202 (1991).
Curran, et al., "Nitric Oxide and Nitric Oxide-Generating Compounds Inhibit Hepatocyte Protein Synthesis," FASEB J. 5:2085-2092 (1991).
Dalby, et al., "Comparison of Output Particle Size Distributions from Pressurized Aerosols Formulated as Solutions or Suspensions," Pharmacol. Res. 5:36-39 (1988).
Desai, et al., "Involvement of Nitric Oxide in the Reflex Relaxation of the Stomach to Accommodate Food or Fluid," Nature 351:477 (1991).
Dihn Xuan, et al., "Acetylcholine and Adenosine Diphosphate Cause Endothelium-Dependent Relaxation of Isolated Human Pulmonary Arteries," Eur. Respir. J., 3:633-638 (1990).
Dihh Xuan, et al., "Primary Pulmonary Hypertension: Diagnosis, Medical and Surgical Treatment," Resp. Med., 84:189-197 (1990).
Dihn Xuan, et al., "Non-prostanoid Endothelium-Derived Vasoactive Factors," J. Intl. Med. Res. 17:305-315 (1989).
Donahue, et al., "Production of O.sub.3, NO, and N.sub.2 O in a Pulsed Discharge at 1 Atm," Ind. Eng. Chem., 16:208-215 (1977).
Dupuy, et al., "Bronchodilator Action of Inhaled Nitric Oxide in Guinea Pigs," J. Clin. Invest. 90:421-428 (1992).
Dworetz, et al., "Survival of Infants with Persistent Pulmonary Hypertension without Extracorporeal Membrane Oxygenation," Pediatrics, 84:1-6 (1989).
Edwards, et al., "Activation of Hepatic Guanylate Cyclase by Nitrosyl-Heme Complexes," Biomed. Pharmacol. 30:2531-2538 (1981).
Fishman, "Pulmonary Hypertension and Cor Pulmonate," Pulmonary Diseases and Disorders, 2nd Ed., vol. 2 McGraw-Hill, New York, Chapter 64, pp. 999-1048.
Flavahan, et al., "Respiratory Epithelium Inhibits Bronchial Smooth Muscle Tone," J. Appl. Physiol. 58:834-838 (1985).
Flentley, "Today's Treatment of Airway Obstruction . . . and Tomorrow's?", Respiration 55:4-9 (1989).
Foubert, et al., "Safety Guidelines for Use of Nitric Oxide," Lancet 339:1616 (1992).
Fox, et al., "Pulmonary Hypertension in the Perinatal Aspiration Syndromes," Pediatrics 59:205-211 (1977).
Fratacci, et al., "Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator of Heparin-Protamine Vasoconstriction in Sheep," Anesthesiology 75:990-999 (1991).
Frostell, et al., "Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator Reversing Hypoxic Pulmonary Vasoconstriction," Circulation 83:2038-2047 (1991).
Frostell et al., "Inhaled Nitric Oxide Selectively Reverses Human Hypoxic Pulmonary Vasoconstriction Without Causing Systemic Vasodilation," Anesthesiology 78:427-35 (1993).
Furchgott, et al., "Endothelium-Derived Relaxing and Contracting Factors," FASEB J. 3:2007-2018 (1989).
Garg, et al., "Nitric Oxide Generating Vasodilators Inhibit Mitogenesis and Proliferation of BALB/C 3T3 Fibroblasts by a Cyclic GMP-Independent Mechanism," Biochem. Biophys. Res. Commun. 171:474-479 (1990).
Garg, et al., "Nitric Oxide Generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit . . . Vascular Smooth Muscle Cells," J. Clin. Invest. 83:1774-1777 (1989).
Gilman, et al., "Vascular Effects of Cigarette Smoke in Isolated Pig Lungs," Am. Rev. Respir. Dis. 124:549-553 (1981).
Gold, et al., "Animal Models for Arterial Thrombolysis and Prevention of Reooculsions," Circulation, 83:26-40 (1991).
Groves, et al., "SIN-1 Reduces Platelet Adhesion and Platelet Thrombus Formation in a Porcine Model of Balloon Angioplasty," Circulation 87:590-597 (1993).
Heaslip, et al., "Co-Regulation of Tracheal Tone by Cyclic AMP- and Cyclic GMP-Dependent Mechanisms," J. Pharmacol. Exp. Ther., 243:1018-1026 (1987).
Higgenbottam, et al.,"Inhaled Endothelium Derived-Relating Factor (EDDIF) in Primary Hypertension (PPH)," Am. Rev. Resp. Dis. Suppl. 137:107, (1988).
Hogman, et al., "Prolonged Bleeding Time During Nitric Oxide Inhalation in the Rabbit," Acta. Physiol.Scand. 151:125-129 (1994).
Hogman, et al., "Bleeding Time Prolongation and NO Inhalation," Lancet, 341:1664-1665 (1993); Abstract.
Hounam, et al., "Particle Depositions", Respiratory Defense Mechanisms, Part 1, pp. 125-156 (1977).
Hugod, "Effect of Exposure to 43 ppm Nitric Oxide and 3.6 ppm Nitrogen Dioxide on Rabbig Lung," Int. Arch. Occup. Environ. Health 42:159-167 (1979).
Ichinose, et al., "Pro
Bloch Kenneth D.
Zapol Warren M.
Harrison Robert H.
The General Hospital Corporation
LandOfFree
Treatment of vascular thrombosis and restenosis with inhaled nit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of vascular thrombosis and restenosis with inhaled nit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of vascular thrombosis and restenosis with inhaled nit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1758630